NCT01154816 2020-05-13Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaChildren's Oncology GroupPhase 2 Completed118 enrolled 24 charts
NCT02560025 2020-05-05Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLMassachusetts General HospitalPhase 2 Completed42 enrolled 12 charts
NCT01567709 2018-04-11Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaNational Cancer Institute (NCI)Phase 1 Completed34 enrolled
NCT01466881 2016-03-10Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 2 Completed42 enrolled 10 charts